Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05322070 · ClinicalTrials.gov registry record · Phase 4

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

A Phase 4 study of Uveitis, Posterior, sponsored by Alimera Sciences.

Active
Registry status
Phase 4
Development phase
125
Enrollment target
20
Study locations

NCT05322070: Active Phase 4 study of Uveitis, Posterior, sponsored by Alimera Sciences.

NCT05322070 is a Phase 4 study of Uveitis, Posterior that is active but no longer recruiting, run by Alimera Sciences. The registered enrollment target is 125 participants, below the 139-participant average among 6 other Uveitis, Posterior trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05322070, a Phase 4 study of Uveitis, Posterior, is active but no longer recruiting, sponsored by Alimera Sciences.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
125 participants
Enrollment target
20
Study locations

Study Summary

A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uveitis (intraocular inflammation) that has responded to previous steroid therapy.

Conditions Studied

Interventions

  • DRUG Fluocinolone Acetonide Intravitreal Implant 0.18 mg

Study Locations (20)

California

  • Retina Consultants of Orange County - Fullerton
  • Macula and Retina Institute - Glendale
  • California Eye Specialists Medical Group - Pasadena
  • Retinal Consultants Medical Group - Sacramento

Florida

  • Advanced Research - Coral Springs
  • Retina Specialists of Tampa - Wesley Chapel

Illinois

  • Retinal Vitreal Consultants Ltd. - Chicago
  • Illinois Retina Associates, S.C. - Oak Park

Massachusetts

  • Opthalmic Consultants of Boston - Boston
  • Massachusets Eye Research and Surgery Institution - Waltham

Colorado

  • Retina Associates of Colorado - Lakewood

Georgia

  • Marietta Eye Clinic - Marietta

Maryland

  • Cumberland Valley Retina Consultants - Hagerstown

Michigan

  • Foundation for Vision Research - Grand Rapids

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2022-06-06
Est. Completion 2025-11
Phase Phase 4
Alimera Sciences

8 total trials

What the registry record for NCT05322070 still lists

NCT05322070 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 139-participant average among 6 other Uveitis, Posterior trials with a reported enrollment target (10% lower).

The record links to 1 condition, with Uveitis, Posterior appearing as the primary indexed condition, and to 1 intervention - of which Fluocinolone Acetonide Intravitreal Implant 0.18 mg is the first listed.

NCT05322070 names 20 study sites across 14 states, led by California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT05322070 about?

NCT05322070 is a clinical study titled "Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis". A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uveitis (intraocular inflammation) that has responded to previous steroid therapy.

What is the current status of trial NCT05322070?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 125 participants. The study started on 2022-06-06. Estimated completion is 2025-11.

What conditions does trial NCT05322070 study?

This clinical trial studies the following conditions: Uveitis, Posterior.

What interventions are being tested in trial NCT05322070?

The interventions under investigation include: Fluocinolone Acetonide Intravitreal Implant 0.18 mg (DRUG).

Who is sponsoring clinical trial NCT05322070?

This trial is sponsored by Alimera Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05322070 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Uveitis, Posterior

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02717039 · 125 participants

    Pharmacogenomics of Heparin-Induced Thrombocytopenia

  • NCT02763033 · 125 participants · Phase 2

    Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients

  • NCT02793999 · 125 participants

    Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia

  • NCT03003299 · 125 participants · NA

    PARTNER 3 Trial - Aortic Valve-in-Valve

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05322070, the US trial registry maintained by the National Library of Medicine. NCT05322070 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.